样式: 排序: IF: - GO 导出 标记为已读
-
Cardiovascular effects of antiobesity drugs: are the new medicines all the same? Int. J. Obesity Suppl. Pub Date : 2020-07-20 Mauro Cataldi,Angelo Cignarelli,Francesco Giallauria,Giovanna Muscogiuri,Luigi Barrea,Silvia Savastano,Annamaria Colao,
Waiting for a definite answer from well-designed randomized prospective clinical trials, the impact of the new antiobesity drugs -liraglutide, bupropion/naltrexone, phentermine/topiramate and lorcaserin- on cardiovascular outcomes remains uncertain. What has been learned from previous experience with older medicines is that antiobesity drugs may influence cardiovascular health not only causing weight
-
What is the best diet for cardiovascular wellness? A comparison of different nutritional models. Int. J. Obesity Suppl. Pub Date : 2020-07-20 Silvia Migliaccio,Caterina Brasacchio,Francesca Pivari,Ciro Salzano,Luigi Barrea,Giovanna Muscogiuri,Silvia Savastano,Annamaria Colao,
Cardiovascular diseases (CVD) represent to date the leading cause of mortality in both genders in the developed countries. In this context, a strong need for CVD prevention is emerging through lifestyle modification and nutrition. In fact, several studies linked CVD with unhealthy nutrition, alcohol consumption, stress, and smoking, together with a low level of physical activity. Thus, the primary
-
Maternal obesity: focus on offspring cardiometabolic outcomes. Int. J. Obesity Suppl. Pub Date : 2020-07-20 Alessandra Gambineri,Alessandro Conforti,Andrea Di Nisio,Daniela Laudisio,Giovanna Muscogiuri,Luigi Barrea,Silvia Savastano,Annamaria Colao,
Several human and animal studies have demonstrated that cardiometabolic parameters in infancy, childhood, adolescence and even adulthood are negatively influenced by many factors besides energy imbalance. Interestingly, maternal weight excess both before and during pregnancy seems to be a negative determinant of metabolic and cardiovascular outcomes in the offspring. This review includes both human
-
Nutrigenetics-personalized nutrition in obesity and cardiovascular diseases. Int. J. Obesity Suppl. Pub Date : 2020-07-20 Luigi Barrea,Giuseppe Annunziata,Laura Bordoni,Giovanna Muscogiuri,Annamaria Colao,Silvia Savastano,
Epidemiological data support the view that both obesity and cardiovascular diseases (CVD) account for a high proportion of total morbidity and mortality in adults throughout the world. Obesity and CVD have complex interplay mechanisms of genetic and environmental factors, including diet. Nutrition is an environmental factor and it has a predominant and recognizable role in health management and in
-
Sleep disturbances: one of the culprits of obesity-related cardiovascular risk? Int. J. Obesity Suppl. Pub Date : 2020-07-20 Giovanna Muscogiuri,Dario Tuccinardi,Vincenzo Nicastro,Luigi Barrea,Annamaria Colao,Silvia Savastano,
Growing evidence suggested that Sleep Disorders (SD) could increase the risk of developing obesity and could contribute to worsen obesity-related cardiovascular risk. Further, obesity per se has been reported to blunt sleep homeostasis. This happens through several mechanisms. First of all, the excessive adipose tissue at neck and chest levels could represent a mechanical obstacle to breathe. Moreover
-
From obesity through gut microbiota to cardiovascular diseases: a dangerous journey. Int. J. Obesity Suppl. Pub Date : 2020-07-20 Paolo Marzullo,Laura Di Renzo,Gabriella Pugliese,Martina De Siena,Luigi Barrea,Giovanna Muscogiuri,Annamaria Colao,Silvia Savastano,
The co-existence of humans and gut microbiota started millions of years ago. Until now, a balance gradually developed between gut bacteria and their hosts. It is now recognized that gut microbiota are key to form adequate immune and metabolic functions and, more in general, for the maintenance of good health. Gut microbiota are established before birth under the influence of maternal nutrition and
-
The 17th international symposium in obesity; targeting the gut to treat obesity and its metabolic comorbidities Int. J. Obesity Suppl. Pub Date : 2016-11-16 Denis Richard
Introduction
-
Nutritionist and obesity: brief overview on efficacy, safety, and drug interactions of the main weight-loss dietary supplements Int. J. Obesity Suppl. Pub Date : 2019-04-12 Luigi Barrea, Barbara Altieri, Barbara Polese, Barbara De Conno, Giovanna Muscogiuri, Annamaria Colao, Silvia Savastano
Over the past 20 years the use of dietary supplements as adjuvant therapy for weight loss gained growing favor among consumers and dietician–nutritionists, with the subsequent astounding increase in health costs. Despite the reassuring label of natural remedy for losing weight, dietary supplements contain a wide variety of ingredients on which available information is rather scanty and scientifically
-
Taste and the Gastrointestinal tract: from physiology to potential therapeutic target for obesity Int. J. Obesity Suppl. Pub Date : 2019-04-12 Giovanni Sarnelli, Giuseppe Annunziata, Silvia Magno, Claudia Oriolo, Silvia Savastano, Annamaria Colao
Flavor is the combination of gustatory, olfactory and trigeminal sensations, representing the three main sensory pathways that allow detecting environmental chemical substances. Taste, in particular, is a complex chemosensory path that allows identification of substances present in ingested foods and beverages. In this manuscript, we propose a conceptual roadmap from aspects related to the evolution
-
How much does obesity affect the male reproductive function? Int. J. Obesity Suppl. Pub Date : 2019-04-12 Giuseppe Bellastella, Davide Menafra, Giulia Puliani, Annamaria Colao, Silvia Savastano
-
Obesity and hypovitaminosis D: causality or casualty? Int. J. Obesity Suppl. Pub Date : 2019-04-12 Silvia Migliaccio, Andrea Di Nisio, Chiara Mele, Lorenzo Scappaticcio, Silvia Savastano, Annamaria Colao
-
Female infertility: which role for obesity? Int. J. Obesity Suppl. Pub Date : 2019-04-12 Alessandra Gambineri, Daniela Laudisio, Chiara Marocco, Stefano Radellini, Annamaria Colao, Silvia Savastano
-
Gut microbiota: a new path to treat obesity Int. J. Obesity Suppl. Pub Date : 2019-04-12 Giovanna Muscogiuri, Elena Cantone, Sara Cassarano, Dario Tuccinardi, Luigi Barrea, Silvia Savastano, Annamaria Colao
-
Abstracts from the 5th UK Congress on Obesity 2018: Author Index Int. J. Obesity Suppl. Pub Date : 2018-08-30
Sponsorship: Publication of this supplement was sponsored by the Association for the Study of Obesity (ASO). All content was reviewed and approved by the ASO Committee, which held full responsibility for the abstract selections.
-
Abstracts from the 5 th UK Congress on Obesity 2018: Oral Presentation Abstracts Int. J. Obesity Suppl. Pub Date : 2018-08-30
September 6-7 2018, Newcastle University, Newcastle, United Kingdom Sponsorship: Publication of this supplement was sponsored by the Association for the Study of Obesity (ASO). All content was reviewed and approved by the ASO Committee, which held full responsibility for the abstract selections.
-
Abstracts from the 5 th UK Congress on Obesity 2018: Award Presentation Abstracts Int. J. Obesity Suppl. Pub Date : 2018-08-30
September 6-7 2018, Newcastle University, Newcastle, United Kingdom Sponsorship: Publication of this supplement was sponsored by the Association for the Study of Obesity (ASO). All content was reviewed and approved by the ASO Committee, which held full responsibility for the abstract selections.
-
Abstracts from the 5 th UK Congress on Obesity 2018: Organising Committee Int. J. Obesity Suppl. Pub Date : 2018-08-30
September 6-7 2018, Newcastle University, Newcastle, United Kingdom Sponsorship: Publication of this supplement was sponsored by the Association for the Study of Obesity (ASO). All content was reviewed and approved by the ASO Committee, which held full responsibility for the abstract selections.
-
Abstracts from the 5 th UK Congress on Obesity 2018: Program Listing Int. J. Obesity Suppl. Pub Date : 2018-08-30
-
Abstracts from the 5 th UK Congress on Obesity 2018: Poster Presentation Abstracts Int. J. Obesity Suppl. Pub Date : 2018-08-30
Sponsorship: Publication of this supplement was sponsored by the Association for the Study of Obesity (ASO). All content was reviewed and approved by the ASO Committee, which held full responsibility for the abstract selections.
-
Targeting the gut to treat obesity and its metabolic consequences: view from the Chair Int. J. Obesity Suppl. Pub Date : 2016-11-16 K A Sharkey
The neurohumoral signaling systems of the gastrointestinal (GI) tract are considered the most significant of the peripheral inputs controlling both food intake in the short term and energy balance over a longer time course. The importance of the GI tract in the control of energy balance is underscored by the marked beneficial effects of bariatric surgeries for the treatment of obesity. Despite their
-
Targeting the gut to treat obesity and its metabolic comorbidities: focus on bariatric surgery - view from the chair Int. J. Obesity Suppl. Pub Date : 2016-11-16 A C Carpentier
Over the past decade, bariatric surgery emerged as the most effective treatment modality for obesity and its complications, especially type 2 diabetes. Initially introduced on the basis of their capacity to restrict food intake and/or induce dietary fat malabsorption, the current bariatric surgery procedures result in many more physiological changes that may also partly explain their potent and sustained
-
Bugs, guts and brains, and the regulation of food intake and body weight Int. J. Obesity Suppl. Pub Date : 2016-11-16 M K Hamilton, H E Raybould
-
Gut hormones such as amylin and GLP-1 in the control of eating and energy expenditure Int. J. Obesity Suppl. Pub Date : 2016-11-16 T A Lutz
The control of meal size is the best studied aspect of the control of energy balance, and manipulation of this system constitutes a promising target to treat obesity. A major part of this control system is based on gastrointestinal hormones such as glucagon-like peptide-1 (GLP-1) or amylin, which are released in response to a meal and which limit the size of an ongoing meal. Both amylin and GLP-1 have
-
Cholecystokinin-induced satiety, a key gut servomechanism that is affected by the membrane microenvironment of this receptor Int. J. Obesity Suppl. Pub Date : 2016-11-16 A J Desai, M Dong, K G Harikumar, L J Miller
-
Interactions between gut microbes and host cells control gut barrier and metabolism Int. J. Obesity Suppl. Pub Date : 2016-11-16 P D Cani
-
Bariatric surgery and obesity: influence on the incretins Int. J. Obesity Suppl. Pub Date : 2016-11-16 B Laferrère
The gut hormone incretins have an important physiological role in meal-related insulin release and post-prandial glucose control. In addition to weight loss, the incretin hormones have a role in glucose control after bariatric surgery. The release of incretins, and specifically of glucagon-like peptide (GLP)-1, in response to the ingestion of nutrients, is greatly enhanced after gastric bypass (RYGBP)
-
Does gastric bypass surgery change body weight set point? Int. J. Obesity Suppl. Pub Date : 2016-11-16 Z Hao, M B Mumphrey, C D Morrison, H Münzberg, J Ye, H R Berthoud